Hims & Hers Health, Inc. (HIMS) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this company have returned +8.3% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Medical Info Systems industry, to which Hims & Hers Health belongs, has lost 9.1% over this period. Now the key question is: Where could the stock be headed in the near term?Alt ...

Key PointsCall option buyers think Starbucks, Pfizer, and Him & Hers Health stocks could see higher prices relatively quickly.All three stocks are offering unjustifiable discounts to their 52-week high prices, becoming targets for options traders. Analysts see at least a double-digit upside through their price targets today, backing these traders up.Options are complicated and not for the faint of heart. While some investors may use them to take on irresponsible leverage levels on their minor positions, oth ...

A six-point argument that shares are a table-pounding opportunity worth scooping up now.Telehealth company Hims & Hers Health (HIMS -4.88%) found itself immersed in controversy recently after some polarizing social media posts by the company's CEO sparked debate. The stock took a bit of a hit as a result Then the company released first-quarter earnings amid the uproar, giving bulls a lot to cheer about.While it's often a bad idea for a company to go anywhere near political discussions, there are enough reas ...

The stock is one of the cheapest high-growth stocks around.Shares of Hims & Hers Health (HIMS -4.88%) jumped following the company's first-quarter earnings report that once again announced surging revenue growth. That performance has helped the stock perform well this year, up about 40%.Let's look at some recent comments from the CEO that caused the stock to dip, the company's recent quarterly results, and whether it's too late to buy the stock.Controversial comments sink stock ahead of earningsHims & Hers ...

Prostock-Studio/iStock via Getty ImagesIntroduction It's been a wild few days for Hims & Hers (NYSE:HIMS) stock. Last Friday, CEO Andrew Dudum posted several controversial tweets on X, one of which included his support for university students to protest "against the genocide of the Palestinian people & for your university's divestment from Israel". This sparked a lot of rage and panic among the investing community, sending HIMS stock 8% lower in a single trading day. Even Shark Tank Co-host Kevin O'Lear ...

Hims & Hers Health, Inc. (HIMS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following yea ...

Strong earnings have sent this healthcare company higher today.Shares of growth stock Hims & Hers Health (HIMS 7.38%) jumped as much as 17.1% in trading on Tuesday after the company reported first-quarter 2024 financial results. As of 3 p.m. ET, shares were holding about an 8.4% gain for the day.Crushing expectationsHims & Hers said revenue for the quarter jumped 46% from a year ago to $278.2 million and sailed past the $268.7 million that analysts were expecting. The company also reported net income of $11 ...

Key PointsShares of Hims & Hers stock rallied double after announcing the company's first quarter 2024 results. Investors now have additional evidence to support a bullish company thesis that could run for the next decade.Bullish EPS projections and price targets suggest the stock still needs to be done rallying.5 stocks we like better than Technology Select Sector SPDR FundShares of Hims & Hers Health Inc. NYSE: HIMS are jumping by as much as 15.5% after the company released its first quarter 2024 earnings ...

财务数据和关键指标变化 - 第一季度收入同比增长46%至2.782亿美元 [13] - 订阅用户同比增长41%至170万 [38][39] - 毛利率同比提升2个百分点至82%以上 [40] - 调整后EBITDA同比增长至3.23亿美元,利润率达到12% [50][51] - 自由现金流达1.19亿美元 [52] 各条业务线数据和关键指标变化 - 个性化订阅用户占比超过35%,较去年同期增长近3倍 [12][39] - 个性化产品带来更高的用户粘性和留存率 [40][41] - 公司将继续扩大个性化产品组合,提升用户体验 [16][17] 各个市场数据和关键指标变化 - 公司正在通过电视等渠道提高品牌知名度,吸引更广泛的消费者 [19][20][21] - 公司正在利用营销作为灵活杠杆,以提高效率和获客 [46][47][49] 公司战略和发展方向及行业竞争 - 公司致力于提供高质量个性化、价格亲民的解决方案,以扩大用户群 [10][11][14][15] - 公司正在投资扩大旗下药房的产能和自动化,以满足不断增长的需求 [28][29][55] - 公司计划在未来几年内推出更多新的个性化产品,覆盖更多健康领域 [30][59] 管理层对经营环境和未来前景的评论 - 公司对未来保持乐观,有信心在2030年前实现20%以上的调整后EBITDA利润率 [50][60][62] - 管理层认为公司的品牌、技术平台和药房能力是未来持续增长的关键 [24][25][26][27] 问答环节重要的提问和回答 问题1 **Allen Lutz 提问** 询问公司客户主动寻找的趋势是否属于新现象,以及对营销费用占比的影响 [64] **Andrew Dudum 和 Yemi Okupe 回答** 解释这一趋势是持续的,得益于个性化产品的不断丰富和价格优势,以及公司利用营销作为灵活杠杆的策略 [65][66][67][69][70] 问题2 **Maria Ripps 提问** 询问公司在定价策略方面的计划,以及是否有特定产品线价格弹性更高 [81] **Yemi Okupe 回答** 表示公司会根据成本效益情况,灵活调整价格或增加其他优惠措施,以提高用户粘性 [82][83][84] 问题3 **Daniel Grosslight 提问** 询问公司在体重管理业务方面的情况,以及是否考虑引入GLP-1类药物 [94] **Andrew Dudum 和 Yemi Okupe 回答** 表示体重管理业务表现良好,公司计划在今年内推出GLP-1类产品,并强调产品质量和安全性的重要性 [95][159][160][163][164]